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Use of RiskModels to Predict Death in the Next Year
Among Individual Ambulatory PatientsWith Heart Failure
Larry A. Allen, MD, MHS; Daniel D. Matlock, MD, MPH; SusanM. Shetterly, MS; Stanley Xu, PhD;
Wayne C. Levy, MD; Laura B. Portalupi, MSW; Colleen K. McIlvennan, DNP, ANP; Jerry H. Gurwitz, MD;
Eric S. Johnson, PhD, MPH; David H. Smith, RPh, MHA, PhD; David J. Magid, MD, MPH
IMPORTANCE The clinical practice guidelines for heart failure recommend the use of validated
risk models to estimate prognosis. Understanding howwell models identify individuals who
will die in the next year informs decisionmaking for advanced treatments and hospice.
OBJECTIVE To quantify how risk models calculated in routine practice estimate more than
50% 1-year mortality among ambulatory patients with heart failure who die in the
subsequent year.
DESIGN, SETTING, AND PARTICIPANTS Ambulatory adults with heart failure from 3 integrated
health systems were enrolled between 2005 and 2008. The probability of death was
estimated using the Seattle Heart Failure Model (SHFM) and theMeta-Analysis Global Group
in Chronic Heart Failure (MAGGIC) risk calculator. Baseline covariates were collected from
electronic health records. Missing covariates were imputed. Estimatedmortality was
compared with actual mortality at both population and individual levels.
MAINOUTCOMESANDMEASURES One-yearmortality.
RESULTS Among 10930 patients with heart failure, the median age was 77 years, and 48.0%
of these patients were female. In the year after study enrollment, 1661 patients died (15.9%
by life-table analysis). At the population level, 1-year predictedmortality among the cohort
was 9.7% for the SHFM (C statistic of 0.66) and 17.5% for theMAGGIC risk calculator
(C statistic of 0.69). At the individual level, the SHFM predicted amore than 50% probability
of dying in the next year for 8 of the 1661 patients who died (sensitivity for 1-year death was
0.5%) and for 5 patients who lived at least a year (positive predictive value, 61.5%). The
MAGGIC risk calculator predicted amore than 50% probability of dying in the next year for 52
of the 1661 patients who died (sensitivity, 3.1%) and for 63 patients who lived at least a year
(positive predictive value, 45.2%). Conversely, the SHFM estimated that 8496 patients
(77.8%) had a less than 15% probability of dying at 1 year, yet this lower-risk end of the score
range captured nearly two-thirds of deaths (n = 997); similarly, the MAGGIC risk calculator
estimated a probability of dying of less than 25% for themajority of patients who died at
1 year (n = 914).
CONCLUSIONSANDRELEVANCE Althoughheart failure riskmodels perform reasonablywell at
thepopulation level, theydonot reliably predictwhich individual patientswill die in thenext year.
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A n accurate assessment of short-termmortality is cen-tral to the care of patients with heart failure. Implant-able cardioverter-defibrillators are reserved for pa-
tients “who have a reasonable expectation of meaningful
survival formore than 1 year.”1(pe183) Left ventricular assist de-
vicesandtransplantationare restrictedtopatientswhose1-year
mortalitywithout surgeryexceeds theexpectedmortalitywith
surgery (approximately20%amongpatientswithadurable left
ventricular assist device).2 Hospice eligibility relies on a phy-
sician’s certification “that the patient’s life expectancy is 6
months or less.”2(p32 176)
Guidelines recommendusingvalidated risk scores to esti-
mate the risk ofmortality for patients with heart failure,1 and
those “whoare at high-risk for 1-yearmortalityusingprognos-
ticmodels shouldbe referred for advanced therapy.”3(p159) The
SeattleHeart FailureModel (SHFM) iswell-validated,4-6 com-
monly used, and available online (https://depts.washington
.edu/shfm/).7TheMeta-AnalysisGlobalGroup inChronicHeart
Failure (MAGGIC) riskcalculator isvalidated, increasinglyused,
andavailableonline (http://www.heartfailurerisk.org).8Yet, the
application of population-risk data to individual treatment
decisions has rarely been characterized.9,10We compared the
SHFMandMAGGICriskcalculatorestimateswithactualdeaths
at 1 year among a cohort of ambulatory patients with heart
failure, for the overall population and for individual patients.
Methods
All ambulatory patients 21 years of age or olderwith a diagno-
sisofheart failure11,12duringtheperiodfrom2005to2008were
identified from Kaiser Permanente Colorado, Kaiser Perma-
nenteNorthwest, andFallonHealth.Baselinecovariates for the
risk calculators (Table 1)were extracted fromelectronichealth
records. Deaths were identified from health plan databases,
state death certificates, and Social Security Administration
files.13
The SHFMandMAGGIC risk calculator scoreswere calcu-
lated using the online algorithms.7,8 Mimicking the calcula-
tors, we imputed themean values formissing data. NewYork
HeartAssociation functional class, available in routinecarebut
unavailable in electronic records, was set to functional class
III in primary analysis and class IV in secondary analysis. To
addressconcernsaboutmodel transportability,weupdated the
interceptandparameterestimates.TheSHFMscoreswerecon-
verted to estimated survival at specific timesusing the follow-
ing function: survival (t) = exp (−0.0405t)e(SHFM score), where
t is time. The MAGGIC risk calculator estimates for mortality
were mapped based on probabilities for the integer scores 0
to 50, as described in the original derivation.8 Following the
publishedmethod,8 we usedmultiple imputation for the left
ventricular ejection fraction, bodymass index, systolic blood
pressure, serum creatinine level, and smoking status. The
MAGGIC risk calculator uses the left ventricular ejection frac-
tion in interactions with age and systolic blood pressure, so
weperformed a secondary analysis restricted to personswith
left ventricular ejection fraction data. Actual survival was
described using life-table analyses to handle truncated
follow-up.14 The institutional review boards at the 3 partici-
pating sites approved the study, andwaiver of consentwasob-
tained because of the nature of the study.
Results
Among 10930patientswithheart failure, themedian agewas
77 years, and 48.0% of these patients were female (Table 1).
In the year following registry inclusion, 1661 patients died
(15.9% by life-table analysis).
Reflectingnaturalisticdatacapture,75%of thepatientshad
at least 15 of the 20 SHFMcovariates (range, 11-19 covariates).
At the population level, the SHFM estimated that the 1-year
mortality rate was 9.7%, with amedian life expectancy of 7.0
years (interquartile range,5.3-9.0years; range,3months [short-
est predicted remaining survival of anyone in the cohort] to
22 years [longest]). Discrimination was similar to other co-
horts: the C statistic was 0.69 at 6months, 0.66 at 1 year, and
0.65 at 3 years. Model calibration showed underestimations:
a6-monthpredictedmortality rateof5.0%vsanobservedmor-
tality rate of 10.5%; a 1-year predicted mortality rate of 9.7%
vs an observedmortality rate of 15.9%; and a 3-year predicted
mortality rateof 24.6%vsanobservedmortality rateof 33.6%.
TheHosmer-Lemeshow test suggested an adequatemodel fit
(χ2 = 8.7, P = .36).
At the individual level, the SHFM performed poorly
(Figure). The SHFMpredicted amore than 50%mortality rate
in the next year for 8 of the 1661 patients who actually died
(sensitivity for 1-year death was 0.5%) and for 5 patients who
livedat least a year (positivepredictivevalue, 61.5%) (Table 2).
In secondary analysis forcing theNewYorkHeart Association
to theworst functional class, the SHFMpredicted amore than
50% 1-year mortality rate among 49 patients who died (sen-
sitivity, 3.0%) and among 47 patientswho lived at least a year
(positive predictive value, 51.0%). Updating the SHFM inter-
cept andparameterestimates to recalibrateand refit themodel
(which could not be done in clinical practice), we found that
the C statistic improved (0.75) but still captured less than 8%
of patients who died in the next year (of 191 patients pre-
dicted to die, 123 actually died). Conversely, the SHFM esti-
mated that 8496 patients (77.7%) had amore than 85% prob-
abilityof surviving 1year, yet this “lower-risk”endof the score
range captured nearly two-thirds of deaths (n = 997).
Key Points
Question Howwell do heart failure risk models perform in
identifying which patients will die in the next year?
Findings In this cohort study of 10 930 adults with heart failure,
1661 patients died in the next year. One risk model predicted a
more than 50% probability of dying for only 8 of those patients,
and another risk model predicted death for only 52 of those
patients.
Meaning Heart failure risk models perform reasonably well at the
population level, but they do not reliably predict which individual
patients will die in the next year.
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Table 1. Baseline Characteristics Used in the SHFM and theMAGGIC Score Calculation
Variable
Patients, No. (%)
(N = 10 930)
Covariate
SHFM MAGGIC
Age, mean [SD], y 75.1 [11.8] x x
Male sex 5681 (52.0) x x
NYHA classa x x
Weight,b mean [SD], kg 84.8 [24.2] x
BMI x
<15 10 (0.1)
15-19 336 (3.1)
20-24 1776 (16.2)
25-29 2629 (24.1)
≥30 3480 (31.8)
Missing 2699 (24.7)
LVEF category x x
Preserved (≥50%) 4155 (38.0)
Borderline (41%-49%) 1330 (12.2)
Reduced (≤40%) 3019 (27.6)
Missing 2426 (22.2)
SBP, mean [SD], mm Hg 129.2 [22.9] x x
<110 1524 (13.9)
110-119 1389 (12.7)
120-129 1739 (15.9)
130-139 1511 (13.8)
140-149 1203 (11.0)
≥150 1503 (13.8)
Missing 2061 (18.9)
Ischemic etiology 2239 (20.5) x
Prescription drug use
ACE inhibitor 4499 (41.2) x
ARB 1303 (11.9) x
ACE inhibitor/ARB 5705 (52.2) x
β-Blocker 6374 (58.3) x x
Statin 4734 (43.3) x
Allopurinol 637 (5.8) x
Aldosterone blocker 1106 (10.1) x
Furosemide equivalents,c mg
(24-h dose)
x
No loop diuretic Rx 5471 (50.1)
<20 16 (0.1)
20 2287 (20.9)
27d 127 (1.2)
40 2474 (22.6)
53d 156 (1.4)
80 286 (2.6)
100 84 (0.8)
200 29 (0.3)
(continued)
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For the more stringent hospice referral threshold, the
SHFM identified only 2 patients with a more than 50% prob-
ability of dying within 6 months, neither of whom died
(5 patients had a New York Heart Association functional
class set to IV). For a lower threshold of less than 20% 1-year
mortality (which can guide a durable left ventricular assist
device), the SHFM showed a sensitivity of 20.7%, a specific-
ity of 93.1%, a positive predictive value of 39.6%, and a
negative predictive value of 84.4%.
Analysis was repeated using the MAGGIC risk calculator.
At the population level, the median score was 26 with a pre-
dicted 1-year mortality rate of 17.5%. The C statistic at 1 year
was 0.69. The Hosmer-Lemeshow statistic had a χ2 of 38.6
(P < .001), indicating some lackof fit in this population. In sec-
ondary analyses among the 8504 patients with available left
ventricular ejection fraction data, overall risk of death was
lower (1150died [13.5%]), theCstatisticwas0.70, and theHos-
mer-Lemeshow χ2 was 16.9 (P = .02).
At the individual level, the MAGGIC risk calculator also
performed poorly (Figure). It predicted a more than 50%
mortality rate in the next year for 52 of the 1661 patients who
actually died (sensitivity, 3.1%) and for 63 patients who lived
Table 1. Baseline Characteristics Used in the SHFM and theMAGGIC Score Calculation (continued)
Variable
Patients, No. (%)
(N = 10 930)
Covariate
SHFM MAGGIC
Laboratory data
Hemoglobin,e mean [SD], g/dL 13.0 [1.9] x
Lymphocyte,d,f mean [SD], % 22.3 [9.9] x
Uric acid,d,g mean [SD], mg/dL 7.54 [2.3] x
Total cholesterol,h mean [SD], mg/dL 155.7 [42.3] x
Sodium,i mean [SD], mEq/L 139.1 [3.8] x
Serum creatinine, mg/dL x
<1.02 4032 (36.9)
1.02-1.23 2127 (19.5)
1.24-1.46 1386 (12.7)
1.47-1.69 889 (8.1)
1.70-1.91 632 (5.8)
1.92-2.36 394 (3.6)
2.37-2.82 206 (1.9)
≥2.83 388 (3.5)
Missing 876 (8.0)
Device
ICD 632 (5.8) x
CRT 583 (5.3) x
Comorbidity
Diabetes 1812 (16.6) x
Lung diseasej 3957 (36.2) x
HF diagnosis ≤18 mo 6394 (58.5) x
Current smokerk 390 (3.6) x
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II
receptor blocker; BMI, bodymass index (calculated as weight in kilograms
divided by height in meters squared); CRT, cardiac resynchronization therapy;
HF, heart failure; ICD, implantable cardioverter-defibrillator; MAGGIC,
Meta-Analysis Global Group in Chronic Heart Failure; NYHA, New York Heart
Association; LVEF, left ventricular ejection fraction; Rx, prescription;
SBP, systolic blood pressure; SHFM, Seattle Heart Failure Model.
SI conversion factors: To convert hemoglobin to grams per liter, multiply by
10.0; uric acid to micromoles per liter, multiply by 59.485; total cholesterol to
millimoles per liter, multiply by 0.0259; sodium tomillimoles per liter, multiply
by 1.0; serum creatinine to micromoles per liter, multiply by 88.4.
a Missing data for 10 930 patients (100%).
bWeight in kilograms is not directly in the SHFMmodel but is used to calculate
furosemide dose per kilograms per day. Weight was missing for 16.1% of
patients receiving furosemide and for 2148 patients (19.7%) in our study.
c Bumetanide (dose equivalent conversion 3mg = 80mg of furosemide);
toresmide (dose equivalent conversion 1 mg = 2mg of furosemide).
dData only collected from Kaiser Permanente Colorado; the other 2 sites used
default for 100% ofmedical records.
e Missing data for 2043 patients (18.7%).
f Missing data for 8453 patients (77.3%).
gMissing data for 10 583 patients (96.8%).
hMissing data for 3383 patients (31.0%).
i Missing data for 1384 patients (12.7%).
j TheMAGGIC risk calculator uses the presence or absence of chronic
obstructive pulmonary disease; an only slightly broader variable for pulmonary
disease is available in these data.
k Missing data for 6916 patients (63.3%).
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at least a year (positive predictive value, 45.2%) (Table 2).
Conversely, the MAGGIC risk calculator estimated that 8161
patients (74.7%) had amore than 75% probability of surviving
1 year, yet this “lower-risk” end of the score range captured
the majority of deaths (n = 914). For the lower threshold of
less than 20% 1-year mortality, the MAGGIC risk calculator
showed a sensitivity of 69.7%, a specificity of 61.2%, a posi-
tive predictive value of 28.1%, and a negative predictive value
of 90.3%.
Discussion
In this cohort of more than 10000 ambulatory patients with
heart failure,well-accepted riskmodels assigned amore than
50% chance of death in the next year to a very small fraction
of those who actually died. Conversely, the majority of pa-
tients who died had amore than 75%model-estimated prob-
ability of surviving beyond 1 year. This highlights the limita-
tions of applying population-based prognostic model results
to short-termmedical decisions about individual patients15,16
andmay partially justify the limited uptake of risk models in
routine clinical practice.17
Most research has gone into refining risk models despite
diminishing improvements inperformance.Meanwhile, there
is a dearthof information tohelppatients andhealth carepro-
fessionals manage the uncertainty inherent in survival
estimates.18 Objective risk information should be integrated
with recognition of uncertainty.15,19,20 For example, predic-
tion intervals may be more informative than median
values.21 Rather than say that “your expected survival is
about 1 year,” a clinician could say “if I had 100 people like
you, 25 would die within 6 months and 25 would be alive
after 2 years.”
Limitations
Limitations should be considered. First, missing data requir-
ing imputation may significantly relate to the poor risk pre-
Figure. One-Year Estimated Risk of Death and Actual Death
 
0 2010 30 40 50 60 70 80 90 100
De
ad
≤50% Mortality (Alive) >50% Mortality (Death) ≤50% Mortality (Alive) >50% Mortality (Death)
Al
iv
e
O
bs
er
ve
d 
M
or
ta
lit
y 
at
 1
 y
0 2010 30 40 50 60 70 80 90 100
SHFM-predicted 1-y estimated risk of deathA MAGGIC-predicted 1-y estimated
risk of death
B
SHFM-Predicted Mortality at 1 y
Estimated Risk of Death, % Estimated Risk of Death, %
MAGGIC-Predicted Mortality at 1 y
Accurate predication for individuals
Inaccurate predication for individuals
Shown are the 1-year predictions of death for individuals and associated actual survival using the Seattle Heart Failure Model (SHFM) (A) and theMeta-Analysis
Global Group in Chronic Heart Failure (MAGGIC) risk calculator (B). Each dot represents an individual.
Table 2. Patients Categorized byModel-Predicted and Actual Mortality at 1 Year
Model
1-y Vital Status
No./Total No. (%)Died Lived
SHFM
Predicted survival ≤50% (anticipated dead), No. 8 5 8/13 (61.5)a
Predicted survival >50% (anticipated alive), No. 1653 7616 7616/9269 (82.2)b
No./total No. (%) 8/1661
(0.5)c
7616/7621
(99.9)d
9282e
MAGGIC risk calculator
Predicted survival ≤50% (anticipated dead), No. 52 63 52/115 (45.2)a
Predicted survival >50% (anticipated alive), No. 1609 7558 7558/9167 (82.4)b
No./total No. (%) 52/1661 (3.1)c 7558/7621 (99.2)d 9282e
Abbreviations: MAGGIC,
Meta-Analysis Global Group in
Chronic Heart Failure; SHFM, Seattle
Heart Failure Model.
a Positive predictive value.
bNegative predictive value.
c Sensitivity.
d Specificity.
e A total of 1648 patients were
censored owing to a lack of 1-year
follow-up (25 patients with a
MAGGIC-predicted survival of
50%).
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diction seen in thesemodels; however, imputation replicates
most real-world risk assessments. Second, the model calcu-
lationwas performed someyears ago, but the rates of therapy
and mortality for heart failure remained relatively un-
changed from2005 to 2014.22,23 Finally, the riskmodelswere
developed in cohorts that either reflected secular differences
in time (the SHFM) or geographical differences in care (the
MAGGIC risk calculator). Moreover, the cohort used here—
like any insured population in an integrated health plan—
may fail to track well with the general population. Variability
in the performance of the SFHM and the MAGGIC risk calcu-
lator is to be expected because the derivation cohorts came
from highly orchestrated clinical trial populations instead of
unselected general care patients.
Conclusions
Risk models cannot prospectively identify the vast majority
of individual ambulatory patients whowill die in the near fu-
ture. For undulating diseases such as heart failure, improve-
ments in risk modeling are only a partial solution. Mean-
while,wemustembrace thecertaintyofuncertaintyandbetter
help patients plan for the worst while hoping for the best.
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